MAP1LC3A and breast carcinoma: As shown in Fig. 3a and Additional file 1: Fig. S1d, the combination of CQ plus either ipatasertib or taselisib induced a more robust accumulation of LC3 and p62/SQSTM1 co-aggregates in all breast cancer models.